These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15497908)

  • 21. Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17beta-estradiol and trimegestone versus two regimens combining 1 or 2 mg 17beta-estradiol and norethisterone acetate.
    Gambacciani M; Spielmann D; Genazzani AR
    Gynecol Endocrinol; 2005 Aug; 21(2):65-73. PubMed ID: 16294457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17beta-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a two-year period.
    Pornel B; Spielmann D
    Gynecol Endocrinol; 2005 Aug; 21(2):74-81. PubMed ID: 16294458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women.
    Dinger J; Bardenheuer K; Heinemann K
    Climacteric; 2016 Aug; 19(4):349-56. PubMed ID: 27174159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An empirically validated responder definition for the reduction of moderate to severe hot flushes in postmenopausal women.
    Gerlinger C; Gude K; Hiemeyer F; Schmelter T; Schäfers M
    Menopause; 2012 Jul; 19(7):799-803. PubMed ID: 22228322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials.
    Shulman LP; Yankov V; Uhl K
    Menopause; 2002; 9(3):195-207. PubMed ID: 11973443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women.
    Mattsson LA; Skouby S; Rees M; Heikkinen J; Kudela M; Stadnicki-Kolendo A; Mattila L; Salminen K; Vuorela A; Mustonen M;
    Menopause Int; 2007 Sep; 13(3):124-31. PubMed ID: 17785038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 1-year comparison of the efficacy and clinical tolerance in postmenopausal women of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone.
    Meuwissen JH; Beijers-De Bie L; Vihtamaki T; Tuimala R; Siseles N; Magaril C; The HS; Houben PW; Murga M; Spielmann D; De Villiers TJ
    Gynecol Endocrinol; 2001 Oct; 15(5):349-58. PubMed ID: 11727357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms.
    Speroff L
    Obstet Gynecol; 2003 Oct; 102(4):823-34. PubMed ID: 14551014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of combined drospirenone with estradiol for hypertensive postmenopausal women: a systemic review and meta-analysis.
    Zhao X; Zhang XF; Zhao Y; Lin X; Li NY; Paudel G; Wang QY; Zhang XW; Li XL; Yu J
    Gynecol Endocrinol; 2016 Sep; 32(9):685-689. PubMed ID: 27176003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized trial on the effect of oral combined estradiol and drospirenone on glucose and insulin metabolism in healthy menopausal women with a normal oral glucose tolerance test.
    Depypere H; Dierickx A; Vandevelde F; Stanczyk F; Ottoy L; Delanghe J; Lapauw B
    Maturitas; 2020 Aug; 138():36-41. PubMed ID: 32631586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transdermal estradiol gel for the treatment of symptomatic postmenopausal women.
    Archer DF; Pickar JH; MacAllister DC; Warren MP
    Menopause; 2012 Jun; 19(6):622-9. PubMed ID: 22282101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Micro-dose transdermal estradiol for relief of hot flushes in postmenopausal Asian women: a randomized controlled trial.
    Haines C; Yu SL; Hiemeyer F; Schaefers M
    Climacteric; 2009 Oct; 12(5):419-26. PubMed ID: 19479489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women.
    Joffe H; Hall JE; Gruber S; Sarmiento IA; Cohen LS; Yurgelun-Todd D; Martin KA
    Menopause; 2006; 13(3):411-22. PubMed ID: 16735938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose estradiol for climacteric symptoms in Japanese women: a randomized, controlled trial.
    Honjo H; Taketani Y
    Climacteric; 2009 Aug; 12(4):319-28. PubMed ID: 19330598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief.
    Panay N; Ylikorkala O; Archer DF; Gut R; Lang E
    Climacteric; 2007 Apr; 10(2):120-31. PubMed ID: 17453860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continuous-combined oral estradiol/drospirenone has no detrimental effect on cognitive performance and improves estrogen deficiency symptoms in early postmenopausal women: a randomized placebo-controlled trial.
    Davison SL; Bell RJ; Robinson PJ; Jane F; Leech J; Maruff P; Egan GF; Davis SR
    Menopause; 2013 Oct; 20(10):1020-6. PubMed ID: 23591255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women.
    Pinkerton JV; Shifren JL; La Valleur J; Rosen A; Roesinger M; Siddhanti S
    Menopause; 2003; 10(1):45-52. PubMed ID: 12544676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of drospirenone/estradiol on steroid receptors and Bcl-2 in the postmenopausal endometrium.
    Lima SM; Reis BF; Yamada SS; Postigo S; Grande RM; Botogoski SR; Campaner AB; Hueb CK; Galvão MA
    Climacteric; 2011 Oct; 14(5):551-7. PubMed ID: 21469974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches. A randomized, double-blind placebo-controlled study.
    De Aloysio D; Rovati LC; Giacovelli G; Setnikar I; Bottiglioni F
    Arzneimittelforschung; 2000 Mar; 50(3):293-300. PubMed ID: 10758784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women.
    Archer DF;
    Menopause; 2003; 10(6):516-21. PubMed ID: 14627859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.